Juno Biomedical, Inc. Despite the challenges in translating advanced technologies to healthcare, Juno Biomedical believes in the power of technology to aid in the healing process. Their flagship product, CELLTech™, is a deep brain stimulation (DBS) system designed to restore lost motor function after subacute ischemic stroke.

Currently, their team is working on gaining market clearance through clinical testing and an Investigational Device Exemption (IDE) submission. Led by their visionary Founder and President, Trisha Pfluger, Juno Biomedical is dedicated to uncovering the potential of the human body to repair itself at a cellular and molecular level. With a growing team of experts and partnerships with renowned institutions like Prisma Health-Midlands and the University of South Carolina, Juno Biomedical is at the forefront of medical advancements.

While awaiting FDA approval, Juno Biomedical emphasizes the importance of consulting with your doctor for proper post-stroke treatment. For more information, you can contact Juno Biomedical at info@junobiomedical. com or visit their office in Ontario, CA